ID   Mela14
AC   CVCL_VP46
SY   MELA14
DR   cancercelllines; CVCL_VP46
DR   Wikidata; Q95988713
RX   DOI=10.1158/1538-7445.AM2015-2417;
CC   Doubling time: 30 hours (Direct_author_submission).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (Direct_author_submission).
CC   Miscellaneous: Cell line information from personal communication of Marlow, Laura A.
CC   Derived from site: Metastatic; Small intestine, mesentery; UBERON=UBERON_0001170.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11,12
ST   D16S539: 10,16
ST   D18S51: 10.1,14
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 9,11
ST   D8S1179: 12,14
ST   FGA: 24,26
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 16,20
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   42Y
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 10-04-25; Version: 11
//
RX   DOI=10.1158/1538-7445.AM2015-2417;
RA   Harris A.L., Marlow L.A., Mathias A.C., Dawson L.K., Durham W.F.,
RA   Meshaw K.A., Mullin R.J., Small D.L., Synnott A., Wu K., Milosevic D.,
RA   Netzel B.C., Grebe S.K.G., Markovic S.N., Copland J.A. 3rd;
RT   "Characterization of novel patient derived melanoma xenografts and
RT   cell lines in response to targeted therapies.";
RL   Cancer Res. 75 Suppl. 15:2417-2417(2015).
//